Bullish
$VSTM Mutated (changed) forms of the KRAS gene have been found in some types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. These changes may cause cancer cells to grow and spread in the body. CH+Defactinib combo work well together and is a potential blockbuster combo drug. It’s a potential billion dollar drug if it can be broadly applied to all KRAS / RAF cancer mutations. Some of the response rates they were mentioning on the call were insane. I heard 70-80% ORR mentioned. If they release data 70-80% ORR, they may prove that they may have a synergistic drug combo that could be applicable to any KRAS/RAF mutation. Couple that with manageable toxicity and this moves 100 to 300% in premarket or AH💰Wait for more CH+Defactinib data during 1H 2020. Some big pharma may already call Brian Stuglik about making a deal to get in on the CH+Defactinib combo🤞
  • 9
  • 4